SHIONOGI & CO., LTD.

Shionogi Launches MULPLETA® Tablets 3mg In Japan for Improvement of Thrombocytopenia

Osaka, Japan, December 1, 2015 - Shionogi & Co., Ltd (Head Office: Osaka, Japan; President & CEO: Isao Teshirogi Ph.D.; hereinafter "Shionogi") today announced the launch of MULPLETA® Tablets 3mg, indicated for the improvement of thrombocytopenia associated with chronic liver disease in patients undergoing an elective invasive procedure.

MULPLETA® is a small molecule thrombopoietin (TPO) receptor agonist which was discovered and developed by Shionogi. In this September, this drug was approved in Japan – its first approval worldwide. MULPLETA® is a first-in-class (FIC) drug which increases platelet counts in patients with chronic liver disease in advance of, and in preparation for, elective invasive procedures. This drug is expected to offer alternative to the currently standard approach of platelet transfusion, which can be associated with non-hemolytic adverse reactions, bacterial infections, or viral infections.

Shionogi will strive to achieve its mission to "supply the best possible medicine to protect the health and wellbeing of the patients we serve" and thereby to improve the quality of life for patients all over the world as a drug-discovery-based pharmaceutical company.

Product outline of MULPLETA®

Product name:	MULPLETA® Tablets 3mg
Generic Name:	lusutrombopag
Indication:	Improvement of thrombocytopenia associated with chronic liver disease in patients prior to elective procedures
Dosage and Administration:	3 mg of lusutrombopag once daily orally for 7 days for adult patients
NHI Price:	16,107.6 yen per 3 mg tablet
Approval Date:	September 28, 2015
Launch Date:	December 1, 2015

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For further information, contact:

Corporate Communications, Shionogi & Co., Ltd.

Osaka Tel：06-6209-7885 Fax：06-6229-9596

Tokyo Tel：03-3406-8164 Fax：03-3406-8099